Acute Renal InjuryNCT05186636
Dialyzing Wisely - Improving the Delivery of Acute Renal Replacement Therapy to Albertans
An observational study of Acute Renal Injury, run by University of Alberta at 15 sites in Canada.
Trial summary
Implementation of an evidence-based and best practices acute RRT pathway aiming to decrease acute RRT program and healthcare systems costs while improving important patient-reported outcomes. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Acute Renal Injury
- What is being tested?
- KPI reports and Prescriber reports
- How many people
- 9,348 participants
- Where
- 15 sitesCanada
- Study dates
- 12 Jan 2023to 31 May 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: All patients from 15 adult and 3 pediatric Alberta ICUs who receive acute RRT as part of their usual clinical care during the intervention period
Who may be able to join
- Patient in one of 15 adult and 3 pediatric intensive care units in Alberta Receive acute RRT as part of their usual clinical care during the intervention period
Who cannot join
- none
Trial locations and contacts
15 sites in 1 country.
15 sites in 1 country
Canada15 sites
Peter Lougheed Centre
Calgary, Alberta, T1Y 6J4
Foothills Medical Centre
Calgary, Alberta, T2N 2T9
Rockyview General Hospital
Calgary, Alberta, T2V 1P9
Alberta Children's Hospital
Calgary, Alberta, T3B 6A8
South Health Campus
Calgary, Alberta, T3M 1M4
Royal Alexandra Hospital
Edmonton, Alberta, T5H 3V9
Misericordia Community Hospital
Edmonton, Alberta, T5R 4H5
Manzankowski Alberta Heart Institute
Edmonton, Alberta, T6G 2B7
Stollery Children's Hospital
Edmonton, Alberta, T6G 2B7
University of Alberta Hospital
Edmonton, Alberta, T6G-2B7
Grey Nuns Community Hospital
Edmonton, Alberta, T6L 5X8
Grande Prairie Regional Hospital
Grande Prairie, Alberta, T8V 4B1
Chinook Regional Hospital
Lethbridge, Alberta, T1J 1W5
Red Deer Regional Hospital Centre
Red Deer, Alberta, T4N 4E7
Sturgeon Community Hospital
St. Albert, Alberta, T8N 6C4
About this study
Implementation of an evidence-based and best practices acute RRT pathway aiming to decrease acute RRT program and healthcare systems costs while improving important patient-reported outcomes.
Read the detailed description
Providing acute dialysis to critically ill patients in ICU settings is resource and cost intensive. The daily costs of acute dialysis can range from $528/day for intermittent hemodialysis to $865/day for continuous renal replacement therapy. Providing acute dialysis in ICU settings requires a specialized team of nurses, educators, physicians and stakeholders to ensure its safe and effective prescription and delivery. Acute dialysis is typically delivered to some of the most acutely ill patients admitted to the ICU to support organ function and sustain life.
At present, there is not a standardized approach to the prescription and delivery of acute dialysis therapy in ICUs across Alberta. The DIALYZING WISELY program will implement a standardized approach to the delivery of best practices for acute dialysis therapy to all patients who receive treatment across ICUs in Alberta.
- Conditions
- Acute Renal Injury
- Being tested
- KPI reports, Prescriber reports
- Keywords
- evidence based care pathway,, critical care medicine, quality improvement, acute renal replacement therapy
- Medical subject headings
- Acute Kidney Injury
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
KPI reportsOther
Also called Monitoring, reporting and regular review of acute RRT KPIs
Quarterly
Prescriber reportsOther
Individualized prescriber reports for acute RRT initiation patterns along with targeted education to ensure that align with best evidence-based practices
| Study group | Role | What they receive |
|---|---|---|
| ICU patients receiving renal replacement therapy | All patients in participating ICU's receiving CRRT or IRRT during the study period Receives: Other: KPI reports; Other: Prescriber reports |
What is being measured
The primary outcome is the main question the study is designed to answer.
Key performance indicators (KPI)
Changes in acute KPIs
Measured: Throughout intervention period up to 3 years
Health system costs
Acute RRT and healthcare systems costs
Measured: 3 years
Secondary outcomes (4)
Length of renal replacement therapy
Length of time patient receives RRT during their ICU stay
Measured: 3 years
ICU and hospital lengths of stay
Number of days patient spends in the ICU and hospital
Measured: 3 years
ICU and 90 day mortality
number of patients who die before ICU discharge or within 90 days of ICU stay
Measured: 3 years
Rates of RRT dependence at 90 days
number of patients who are receiving RRT at 90 days after ICU stay
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jan 2022
- Study start12 Jan 2023
- Primary completion31 May 2026
- Study completion31 May 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Acute Renal InjuryStudies of the same condition, open and under way.
- More trials run by University of AlbertaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 9,348 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Alberta
- Sponsor type
- University, hospital or other
- Collaborators
- Alberta Innovates Health Solutions
- Responsible party
- Sponsor
- Investigators
- Oleksa Rewa, MD, Principal investigator, University of Alberta
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05186636
- Sponsor's protocol ID
- Pro00112499
- Status last verified
- Jul 2026
- First submitted
- 9 Dec 2021
- Last updated
- 22 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Opgenorth D, Bagshaw SM, Lau V, Graham MM, Fraser N, Klarenbach S, Morrin L, Norris C, Pannu N, Sinnadurai S, Valaire S, Wang X, Rewa OG. A study protocol for improving the delivery of acute kidney replacement therapy (KRT) to critically ill patients in Alberta - DIALYZING WISELY. BMC Nephrol. 2022 Nov 16;23(1):369. doi: 10.1186/s12882-022-02990-6.
PubMed 36384465
Study at a glance
From the registry record, last updated by the sponsor on 22 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Dialyzing Wisely - Improving the Delivery of Acute Renal Replacement Therapy to Albertans
- ClinicalTrials.gov ID
- NCT05186636
- Acronym / sponsor ID
- Pro00112499
- Conditions
- Acute Renal Injury
- Keywords
- evidence based care pathway,, critical care medicine, quality improvement, acute renal replacement therapy
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 9,348 participants (actual)
- Lead sponsor
- University of AlbertaUniversity, hospital or other
- Collaborators
- Alberta Innovates Health Solutions
- Study start
- 12 Jan 2023 (actual)
- Primary completion
- 31 May 2026 (actual)
- Study completion
- 31 May 2026 (actual)
- First posted
- 11 Jan 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Implementation of an evidence-based and best practices acute RRT pathway aiming to decrease acute RRT program and healthcare systems costs while improving important patient-reported outcomes.
Detailed description
Providing acute dialysis to critically ill patients in ICU settings is resource and cost intensive. The daily costs of acute dialysis can range from $528/day for intermittent hemodialysis to $865/day for continuous renal replacement therapy. Providing acute dialysis in ICU settings requires a specialized team of nurses, educators, physicians and stakeholders to ensure its safe and effective prescription and delivery. Acute dialysis is typically delivered to some of the most acutely ill patients admitted to the ICU to support organ function and sustain life.
At present, there is not a standardized approach to the prescription and delivery of acute dialysis therapy in ICUs across Alberta. The DIALYZING WISELY program will implement a standardized approach to the delivery of best practices for acute dialysis therapy to all patients who receive treatment across ICUs in Alberta.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| ICU patients receiving renal replacement therapy | – | Other: KPI reports, Other: Prescriber reportsAll patients in participating ICU's receiving CRRT or IRRT during the study period |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All patients from 15 adult and 3 pediatric Alberta ICUs who receive acute RRT as part of their usual clinical care during the intervention period
Key inclusion criteria (1 listed)
- Patient in one of 15 adult and 3 pediatric intensive care units in Alberta Receive acute RRT as part of their usual clinical care during the intervention period
Key exclusion criteria (1 listed)
- none
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| KPI reportsAlso: Monitoring, reporting and regular review of acute RRT KPIsQuarterly | Other | ICU patients receiving renal replacement therapy |
| Prescriber reportsIndividualized prescriber reports for acute RRT initiation patterns along with targeted education to ensure that align with best evidence-based practices | Other | ICU patients receiving renal replacement therapy |
Primary outcome
Key performance indicators (KPI)
Time frame: Throughout intervention period up to 3 years
Changes in acute KPIs
Health system costs
Time frame: 3 years
Acute RRT and healthcare systems costs
4 secondary outcomes
Length of renal replacement therapy
Time frame: 3 years
ICU and hospital lengths of stay
Time frame: 3 years
ICU and 90 day mortality
Time frame: 3 years
Rates of RRT dependence at 90 days
Time frame: 3 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jul 2026.
- Derived from this study: PubMed 36384465Opgenorth D, Bagshaw SM, Lau V, Graham MM, Fraser N, Klarenbach S, Morrin L, Norris C, Pannu N, Sinnadurai S, Valaire S, Wang X, Rewa OG. A study protocol for improving the delivery of acute kidney replacement therapy (KRT) to critically ill patients in Alberta - DIALYZING WISELY. BMC Nephrol. 2022 Nov 16;23(1):369. doi: 10.1186/s12882-022-02990-6.
Related trials for Acute Renal Injury
Not yet recruiting
Vitamin C for Acute Kidney Injury in ACLF With Septic Shock: A Randomized Controlled Trial
Acute-on-Chronic Liver Failure (ACLF)
Not yet recruiting
Early Biomarker Kidney Injury Assessment After Acumen Directed Fluid Management in Cardiac Surgery
Renal Injury, Acute Kidney Injury
Recruiting
Acute Kidney Injury and Ultra-endurance Running
AKI (Acute Kidney Injury) Due to Trauma
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
Not yet recruitingObservational study
Diastolic Shock Index for Predicting Hemodynamic Instability During Continuous Renal Replacement Therapy
Acute Kidney Injury, Hypotension (MeSH: D007022)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Oleksa Rewa, MD principal investigator
University of Alberta
15 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Renal Injury, run by University of Alberta at 15 sites in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 15 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Key performance indicators (KPI) (time frame: Throughout intervention period up to 3 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05186636, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2026.